<DOC>
	<DOCNO>NCT00298987</DOCNO>
	<brief_summary>The purpose clinical research study provide dasatinib treatment patient advance chronic myelogenous leukemia ( CML ) Philadelphia chromosome positive acute lymphoblastic leukemia ( Ph+ ALL ) long tolerate treatment imatinib . The safety treatment also study .</brief_summary>
	<brief_title>A Study Dasatinib Patients With Chronic Myelogenous Leukemia Who Are Resistant Intolerant Imatinib Mesylate</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Diagnosis accelerate phase blast phase CML Ph+ ALL Intolerant resistant imatinib mesylate 18 year age old ECOG performance 02 ( great 50 % time bed ) Adequate liver kidney function Pregnant breastfeeding female History significant cardiac disease History significant bleeding disorder ( CML ) Prisoners</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Chronic Myeloid Leukemia Accelerated Blast Phase</keyword>
	<keyword>Leukemia , Acute , Philadelphia-Positive</keyword>
</DOC>